<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03693547</url>
  </required_header>
  <id_info>
    <org_study_id>BG01-1801</org_study_id>
    <nct_id>NCT03693547</nct_id>
  </id_info>
  <brief_title>Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）</brief_title>
  <official_title>Open, Multicenter, Monotherapy, Phase II Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer After Failure or Intolerability to Second-line Standard Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Biostar Technologies, Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chengdu Biostar Pharmaceuticals, Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Biostar Technologies, Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effectiveness and safety of utidelone injection in patients with advanced or
      metastatic NSCLC as a phase II trial
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response to utidelone treatment</measure>
    <time_frame>6 months from first study treatment</time_frame>
    <description>Reflected by percentage of tumor size reduction or regression, assessed by imaging techniques and expressed as Objective Response Rate (ORR）ORR is defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR) according to RECIST. 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>1 year from first study treatment</time_frame>
    <description>PFS is defined as the duration of time from first study treatment to disease progression or death from any cause as documented by the investigator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 year from enrolment</time_frame>
    <description>OS is defined as the duration of time from first study treatment until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events based the Common Terminology Criteria for Adverse Events (CTCAE) version 4·03</measure>
    <time_frame>1 year from first study treatment</time_frame>
    <description>Observe and record incidence of adverse events and severe adverse events associated with utidelone treatment, assessed by investigators according to CTCAE version 4·03</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Advanced Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>utidelone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Utidelone Injection: 30 mg/m2/day, IV on day 1-day 5 of each 21 day cycle, administered to enrolled patients with advanced NSCLC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>utidelone injection</intervention_name>
    <description>utidelone monotherapy in patients with advanced NSCLC by utidelone</description>
    <arm_group_label>utidelone</arm_group_label>
    <other_name>UTD1 injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed non-small cell lung cancer

          2. NSCLC patients who are not suitable for surgery or radical radiotherapy or
             chemotherapy, or who have failed to or are intolerable for standard treatment in local
             advanced or metastatic NSCLC;

          3. NSCLC patients failed or intolerable to previous standard second-line treatment
             (including platinum chemotherapy or targeted therapy);

          4. Patients who did not receive chemotherapy, radiotherapy, surgical therapy, molecularly
             targeted drug therapy, or immunotherapy 4 weeks prior to enrollment;

          5. Age 18 -70 years old, ECOG performance status of 0-1; Life expectancy of 3 months or
             more;

          6. Patients must have measurable disease, defined as at least one target lesion that can
             be accurately measured by imaging techniques in at least one dimension as ≥20 mm with
             conventional computed tomography (CT), ≥10 mm with spiral CT scan (≥15mm for lymph
             node) within 3 weeks before enrolment;

          7. Patients with no brain metastases or with brain metastases but are stable for more
             than 4 weeks after treatment;

          8. Peripheral neuropathy (PN) &lt;grade 2 on the Common Terminology Criteria for Adverse
             Events (CTCAE) version 4.03 within 4 weeks before enrolment;

          9. Patients must have normal haematology as defined below: HGB ≥9 g/L, absolute
             neutrophil count ≥1.5×109/L, platelets ≥80×109/L, bilirubin ≤1.5× the upper limit of
             normal (ULN) (patients with liver metastasis ≤3xULN), aspartate transaminase (AST)/
             alanine transaminase (ALT) ≤2.5 ×ULN (patients with liver metastasis ≤5xULN), and
             creatinine clearance ≥45 mL/min;

         10. Patients with no major organ dysfunctions and heart disease;

         11. Patients who give written informed consent with good compliance.

        Exclusion Criteria:

          1. Patients who are pregnant or breast feeding;

          2. Patients with active tuberculosis

          3. Patients with high possibility of interstitial lung disease ;

          4. Patients with comorbidities, such as carcinomatous meningitis, central nervous system
             (CNS) metastasis, other active malignancies requiring simultaneous treatment, but not
             including cervical cancer in situ or basal cell carcinoma of the skin, severe
             disorders of the heart, lung, liver, or kidneys, severe hypertension, uncontrolled
             diabetes, severe gastrointestinal ulceration, active infections in need of
             antibiotics, or with incontrollable psychiatric history;

          5. patients with HIV, untreated active hepatitis；

          6. Patients with poor compliance;

          7. Patients not fitted for this study determined by the investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YUANKAI SHI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RONGGUO QIU, PhD</last_name>
    <phone>011-86-10-56315388</phone>
    <email>rqiu2001@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>LI TANG, PhD</last_name>
    <phone>011-86-10-56315388</phone>
    <email>tangli63b@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuankai Shi, MD, PhD</last_name>
      <phone>86 10-6778293</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking Union Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Zhao, MD</last_name>
      <phone>011-86-10-69156114</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150081</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gongyan Chen, MD</last_name>
      <phone>011-86-451-86298236</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin People's Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qiang Yao, MD</last_name>
      <phone>011-86-22-87729595</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>July 12, 2020</last_update_submitted>
  <last_update_submitted_qc>July 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

